Clinical Trials Browser

Phase 2 × eltrombopag × 90 days × Clear all

NCT06630221 2026-06-05

Eltrombopag as a Novel Therapeutic Approach for Low-risk MDS and CMML With TET2 Mutations

Phase 2 Suspended

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic